Ionis Pharmaceuticals (IONS) closed at $39.42 on November 6, 2026, up 1.6% from the previous close, on volume of 2,607,739 shares (30-day average 2,854,650).
Data as of November 6, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 8, 2026 | Christmas Tree Put Butterfly | 16-Oct-2655[181x] : 60[135x] : 67.5[46x] P | 3,620 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Ionis plummets as it cuts 2026 revenue guidance for Tryngolza
Seeking Alpha News (Mon, 9-Nov 11:01 AM ET)
Biggest stock movers Monday: NVDA, AMD, VIR, and more
Seeking Alpha News (Mon, 9-Nov 10:32 AM ET)
Globe Newswire (Mon, 9-Nov 10:08 AM ET)
Ionis Pharmaceuticals (IONS) Gets a Buy from Piper Sandler
TipRanks (Mon, 9-Nov 9:25 AM ET)
At a glance: Stocks gapping down premarket
Seeking Alpha News (Mon, 9-Nov 8:51 AM ET)
Ionis: TRYNGOLZA’s Early Market Lead Supports Buy Rating; $100 Price Target Unchanged
TipRanks (Mon, 9-Nov 7:35 AM ET)
Ionis Pharmaceuticals GAAP EPS of -$0.66 beats by $0.55, revenue of $243M beats by $58.62M
Seeking Alpha News (Mon, 9-Nov 7:04 AM ET)
Ionis reports third quarter 2026 financial results and highlights progress on key programs
Business Wire (Mon, 9-Nov 7:00 AM ET)
Here are the major earnings before the open Monday
Seeking Alpha News (Sun, 8-Nov 6:04 PM ET)
Earnings Week Ahead: CSCO, CRWV, PLUG, ALC, AMAT, ACB, RKLB, ASTS, and more
Seeking Alpha News (Sun, 8-Nov 8:07 AM ET)
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
Ionis Pharmaceuticals trades on the NASDAQ stock market under the symbol IONS.
As of November 9, 2026, IONS stock price declined to $28.69 with 5,801,821 million shares trading.
IONS has a beta of 0.62, meaning it tends to be less sensitive to market movements. IONS has a correlation of 0.02 to the broad based SPY ETF.
IONS has a market cap of $4.77 billion. This is considered a Mid Cap stock.
Last quarter Ionis Pharmaceuticals reported $268 million in Revenue and -$.42 earnings per share. This beat revenue expectation by $78 million and exceeded earnings estimates by $.53.
In the last 3 years, IONS traded as high as $86.74 and as low as $23.95.
The top ETF exchange traded funds that IONS belongs to (by Net Assets): VTI, VB, XBI, VBK, VXF.
IONS has underperformed the market in the last year with a price return of -61.3% while the SPY ETF gained +13.1%. IONS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -47.3% and -33.2%, respectively, while the SPY returned -2.1% and -1.3%, respectively.
IONS support price is $38.32 and resistance is $40.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IONS shares will trade within this expected range on the day.
